Reglan (Metoclopramide) and Tardive Dyskinesia: What the Labeling Says

From General Health Awareness to Occupational Risk

If you or a loved one has taken Reglan and noticed uncontrollable facial or limb movements, you may be witnessing tardive dyskinesia. The medical community has long recognized the link between metoclopramide and this neurological condition, with prescribing information now highlighting specific risk factors. This page reviews the published reports and FDA labeling context that shape current understanding of Reglan-induced tardive dyskinesia.

Reglan and Tardive Dyskinesia: A Documented Causal Link

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent used to treat nausea, vomiting, and gastroparesis. Its mechanism of action, while effective for these conditions, can lead to extrapyramidal side effects, including tardive dyskinesia (TD) (https://pubmed.ncbi.nlm.nih.gov/34712535/). TD is a hyperkinetic movement disorder caused by the use of dopamine receptor-blocking agents (DRBAs), a category that includes metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34703232/). The clinical presentation of TD involves potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). These movements are characterized by their involuntary nature and can affect the face, limbs, and trunk, and are associated with increased comorbidities, social stigmatization, and impaired physical and mental health (https://pubmed.ncbi.nlm.nih.gov/34703232/). Once present, TD tends to persist despite dose adjustment or discontinuation of the causative agent (https://pubmed.ncbi.nlm.nih.gov/34703232/). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Reglan regarding the risk of TD. The warning states that metoclopramide, including Reglan, can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA advises using Reglan for the shortest duration of treatment and periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, a total duration of treatment longer than 12 weeks should be avoided; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanistic Pathways and Risk Factors

The mechanistic pathway linking Reglan to TD involves its action as a dopamine D2-receptor blocking agent (https://pubmed.ncbi.nlm.nih.gov/34712535/). This blockade can lead to extrapyramidal side effects, including TD (https://pubmed.ncbi.nlm.nih.gov/34712535/). The FDA's warnings and precautions section further notes that metoclopramide, including Reglan, can cause TD and may also suppress or partially suppress the signs of TD, potentially delaying diagnosis because it may mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warnings also advise avoiding concomitant use of other drugs known to cause TD and avoiding use in patients with Parkinson's Disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If symptoms occur, the FDA recommends discontinuing Reglan and seeking immediate medical attention (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Risk considerations for affected patients include the adequacy of warnings regarding Reglan and TD. The FDA has issued a boxed warning, which is the strongest warning required by the agency, and includes specific contraindications and duration-of-use recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, the occurrence of TD after a single dose of metoclopramide has been reported, as in a case of a postoperative gynecological patient who developed dyskinetic movements after intraoperative administration (https://pubmed.ncbi.nlm.nih.gov/34712535/). This case highlights that while TD is somewhat rare, it can occur even with short-term exposure, and patients may have additional risk factors (https://pubmed.ncbi.nlm.nih.gov/34712535/). Older age is associated with increased risk of TD and with the emergence of TD occurring after shorter treatment durations and lower dosages of DRBAs (https://pubmed.ncbi.nlm.nih.gov/34703232/).

Causation and Clinical Implications

Causation-related considerations for affected patients involve establishing a temporal relationship between Reglan exposure and the onset of TD symptoms. The timeline between exposure and documented harm can vary; while TD typically develops after prolonged use, cases have been documented after a single dose (https://pubmed.ncbi.nlm.nih.gov/34712535/). The FDA's boxed warning emphasizes that the risk increases with duration of treatment and total cumulative dosage, but does not preclude the possibility of TD occurring with shorter exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients who develop TD, the condition tends to persist despite dose adjustment or discontinuation (https://pubmed.ncbi.nlm.nih.gov/34703232/), underscoring the importance of early recognition and adherence to prescribing guidelines. In summary, Reglan (metoclopramide) is a known cause of tardive dyskinesia, a potentially irreversible movement disorder. The FDA has provided clear warnings, including a boxed warning, about this risk, and has specified maximum treatment durations for certain indications. However, cases of TD have been reported after short-term use, including a single dose, and older patients are at increased risk. Affected patients should be aware of the potential for TD, the importance of monitoring for symptoms, and the need to discontinue Reglan if symptoms develop.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Reglan and tardive dyskinesia?

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent that can cause tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA has issued a boxed warning about this risk. TD involves involuntary movements of the face, tongue, trunk, or extremities and can persist even after stopping the medication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Can tardive dyskinesia occur after short-term use of Reglan?

Yes, although the risk increases with longer treatment duration and higher cumulative doses, cases of TD have been reported after a single dose of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/). Older age is also a risk factor for developing TD after shorter exposure (https://pubmed.ncbi.nlm.nih.gov/34703232/).

What should I do if I develop symptoms of tardive dyskinesia while taking Reglan?

If you experience any involuntary movements, especially of the face or tongue, discontinue Reglan and seek immediate medical attention. The FDA recommends stopping the medication and consulting a healthcare provider (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.